Non-Hodgkin's Lymphoma Clinical Trials

A listing of Non-Hodgkin's Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 843 clinical trials
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D) Secondary Objectives: To characterize the safety profile of SAR442257 To characterize the …

ejection fraction
dexamethasone
cutaneous t-cell lymphoma
hodgkin's disease
neuropathy
  • 0 views
  • 19 Feb, 2024
  • 5 locations
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

This study will evaluate the efficacy and safety of camrelizumab in combination with apatinib in in patients with relapsed or refractory diffuse large B cell lymphoma failed from second line chemotherapy.

pulmonary function test
granulocyte colony stimulating factor
g-csf
platelet count
prothrombin time (pt)
  • 0 views
  • 19 Feb, 2024
  • 1 location
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

cns tumors
cellular therapy
non-hodgkin lymphoma
metastasis
pediatric
  • 0 views
  • 19 Feb, 2024
  • 83 locations
Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

This prospectivemulti-centeropen-label, controlled study will evaluate the efficacy and safety of targeted drug in combination with CHOP in treatment of newly diagnosed peripheral T-cell lymphoma.

peripheral t-cell lymphoma
pet/ct scan
t-cell lymphoma
lymphoma
measurable disease
  • 0 views
  • 19 Feb, 2024
  • 1 location
Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy

This prospective, open-label, single-arm study will evaluate the efficacy and safety of azacitidine in combination with chidamide in treatment of newly diagnosed peripheral T-cell lymphoma unfit for conventional chemotherapy.

pet/ct scan
azacitidine
chidamide
tucidinostat
lymphoma
  • 0 views
  • 19 Feb, 2024
  • 1 location
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of VR-CAP (Velcade and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the first-line treatment for patients with marginal zone lymphoma.

marginal zone lymphoma
cyclophosphamide
lymphoma
rituximab
epirubicin
  • 0 views
  • 19 Feb, 2024
  • 1 location
Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma

This prospective pilot study to evaluate the efficacy and safety of the anti-PD-1 antibody combine with Peg-asparaginase and Chidamide regimen for stage IE and IIE ENKTL.

electrocardiogram
biological therapy
frontal sinus
cancer therapy
peg-asparaginase
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy

A study of CT-RD06 cell injection in patients with relapsed or refractory CD19+ B-cell hematological malignancy.

ejection fraction
b-cell acute lymphoblastic leukemia
oximetry
lymphoma
diffuse large b-cell lymphoma
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

A study of CTA101 UCAR-T cell injection in patients with relapsed or refractory CD19+ B-line hematological malignancy

ejection fraction
remission
cell transplantation
b-cell acute lymphoblastic leukemia
oximetry
  • 0 views
  • 19 Feb, 2024
  • 1 location
Ibrutinib + Venetoclax in Untreated WM

This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific MYD88 gene mutation. This research study involves an experimental drug combination of targeted therapies. The names of the study drugs involved in this …

platelet transfusion
ibrutinib
myd88 gene mutation
venetoclax
neutrophil count
  • 0 views
  • 19 Feb, 2024
  • 2 locations